â rsrapport Nycomed - Takeda Pharmaceuticals International GmbH

More documents

Recommendations

Info

ACCOUNTSPARENT COMPANY BALANCE SHEETNoteLIABILITIES31.12.00 31.12.99(000)DKK(000)DKKShare capital 10,010 10,000Share premium 675,427 744,680Retained earnings 0 07 TOTAL SHAREHOLDER’S EQUITY 685,437 755,680Financial institutions 0 27,291Other long term debt 562,982 500,2268 Total long term debt 562,982 527,5178 Repayment of long term debt 0 150,103Trade payables 307 9,1369 Payables to affiliated entities 73,923 010 Other debt 13,538 30,542Total current liabilities 87,768 189,781TOTAL LIABILITIES 650,750 717,298TOTAL SHAREHOLDER’S EQUITY AND LIABILITIES 1,336,187 1,472,97811 Contingent liabilities, guarantee commitments etc.12 Auditor’s remuneration–56–
ACCOUNTSPARENT COMPANY ACCOUNTS NOTES1. Employee relations2000 1998/99(000)DKK(000)DKK7 monthsSalaries and wages etc. are included in the totalexpenses of the group with the following amounts:Employee salaries and wages 5,278 575Pension 0 0Other expenses for social security 2 0Total 5,280 575Which includes compensation to managementand Board of Directors of the parent company:Management 5,280 575Board of Directors 0 0Total 5,280 575Average number of employees 1 12. Financial itemsFinancial incomeInterest income, banks 127 932Interest income, affiliated entities 2,316 0Foreign exchange gain 0 1,465Total 2,443 2,397Financial expensesInterest expenses, banks 3,992 6,096Interest expenses, affiliated entities 533 0Interest expenses, other long term debt 43,109 25,326Foreign exchange loss 1,332 0Total 48,966 31,4223. Income tax expensesParent company:Accrued income tax expenses for the year 0 0Adjustment of deferred tax for the year 0 00 0Subsidiaries:Income tax expenses for the year 14,268 - 2,43914,268 - 2,439Income tax expenses 14,268 - 2,439The parent company has not paid any income taxesduring the year.–57–
Page 2:
CONTENT ANNUAL REPORT3 This is Nyco
Page 6 and 7:
KEY FIGURESDKK million 2000 1999 *)
Page 8 and 9: CHAIRMAN`s REPORTThe Board is very
Page 10 and 11: CHIEF EXECUTIVE OFFICER´s REPORTA
Page 12 and 13: CHIEF EXECUTIVE OFFICER´s REPORTfr
Page 14 and 15: BOARD OF DIRECTORS1092865131171241
Page 16 and 17: MANAGEMENTThe management group in N
Page 18 and 19: BUSINESS DESCRIPTIONNYCOMED MARKETS
Page 26 and 27: BUSINESS DESCRIPTIONMAIN PRODUCTSC
Page 28 and 29: BUSINESS DESCRIPTIONMAIN PRODUCTSTa
Page 30 and 31: BUSINESS DESCRIPTIONMAIN PRODUCTSNy
Page 32 and 33: BUSINESS DESCRIPTIONPRODUCT ORIGINA
Page 34 and 35: BUSINESS DESCRIPTIONPRODUCT ORIGINA
Page 36 and 37: BUSINESS DESCRIPTIONQUALITY ASSURAN
Page 38 and 39: ACCOUNTSCHIEF FINANCIAL OFFICER`s R
Page 40 and 41: ACCOUNTSCHIEF FINANCIAL OFFICER`s R
Page 42 and 43: ACCOUNTSAUDITOR`s REPORT-40-
Page 44 and 45: ACCOUNTSACCOUNTING PRINCIPLESThe re
Page 46 and 47: ACCOUNTSACCOUNTING PRINCIPLESReceiv
Page 48 and 49: ACCOUNTSCONSOLIDATED BALANCE SHEETN
Page 50 and 51: ACCOUNTSCONSOLIDATED ACCOUNTS NOTES
Page 56 and 57: ACCOUNTSPARENT COMPANY PROFIT AND L
Page 60 and 61: ACCOUNTSPARENT COMPANY ACCOUNTS NOT
Page 62 and 63: ACCOUNTSPARENT COMPANY ACCOUNTS NOT
Page 64 and 65: ACCOUNTSOVERVIEW OF SUBSIDIARIESPar
Page 66 and 67: NYCOMED GROUP STRUCTURELEGAL STRUCT
Page 68 and 69: GermanyNycomed Pharma GmbHFraunhofe
show all

â rsrapport Nycomed - Takeda Pharmaceuticals International GmbH

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?

â rsrapport Nycomed - Takeda Pharmaceuticals International GmbH